Viridian Therapeutics Inc(VRDN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:02 PM ET (Korea 11/3 06:02)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.71 | Insider Own | 6.12% | Shs Outstand | 113.2M | Perf Week | 8.4% |
| Market Cap | 2.87B | Forward P/E | - | EPS next Y | 35% | Insider Trans | 20.14% | Shs Float | 106.4M | Perf Month | 30.41% |
| Enterprise Value | 2.23B | PEG | - | EPS next Q | -1.02 | Inst Own | 119.83% | Short Float | 16.93% | Perf Quarter | 21.4% |
| Income | -0.37B | P/S | 40.3 | EPS this Y | -18.28% | Inst Trans | 11.11% | Short Ratio | 10 | Perf Half Y | 79.94% |
| Sales | 0.07B | P/B | 5.08 | EPS next 5Y | 57.67% | ROA | -43.89% | Short Interest | 18.00M | Perf YTD | -18.7% |
| Book/sh | 4.98 | P/C | 2.92 | EPS past 3/5Y | 6.35% 36.07% | ROE | -62.62% | 52W High | -26.22% ($34.29) | Perf Year | 7.07% |
| Cash/sh | 8.66 | P/FCF | - | Sales past 3/5Y | 241.95% 132.18% | ROIC | -40.76% | 52W Low | 91.96% ($13.18) | Perf 3Y | 79.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.06% | Gross Margin | 98.78% | Volatility(W/M) | 4.39% 4.83% | Perf 5Y | 44.41% |
| Dividend TTM | - | EV/Sales | 31.29 | Sales Y/Y TTM | 23220.33% | Oper. Margin | -569.68% | ATR (14) | 1.02 | Perf 10Y | -68.76% |
| Dividend Ex-Date | - | Quick Ratio | 16.95 | EPS Q/Q | 4.56% | Profit Margin | -518.22% | RSI (14) | 72.25 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.95 | Sales Q/Q | 278.67% | SMA20 | 19.09% ($21.24) | Beta | 1.07 | Target Price | $36.2 |
| Payout | - | Debt/Eq | 0.37 | Earnings | 2026/11/4 | SMA50 | 16.72% ($21.68) | Rel Volume | 1.88 | Prev Close | $24.67 |
| Employees | 252 | LT Debt/Eq | 0.37 | EPS/Sales Surpr. | -1.48% 403.55% | SMA200 | 16.5% ($21.72) | Avg Volume(3M) | 1.80M | Price | $25.3 |
| IPO | 2014/6/18 | Option/Short | Yes/Yes | Trades | 23220 | Volume | 3,391,297 | Change | 2.55% |
🧬 This is a US clinical-stage biotech company developing treatments for autoimmune and rare diseases. The company develops antibody candidates targeting autoimmune diseases such as thyroid eye disease, and possesses a late-stage lead candidate along with differentiated dosing options. It is a differentiated autoimmune biotech targeting the unmet market of thyroid eye disease.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded more than usual. That is 188% of its average volume.
Next earnings report: November 4
1 days to go.
VRDN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -18.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,030. Peers typically go for $1,711.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +44.4%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 119.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #75 of 597 in the industry
Based on market cap of $3B.
IDYA#73 Ideaya Biosciences Inc $3B PER - 
DNLI#74 Denali Therapeutics Inc $3B PER - VRDN#75 Viridian Therapeutics Inc $3B PER - 
NRIX#76 Nurix Therapeutics Inc $3B PER 11.1 
BEAM#77 Beam Therapeutics Inc $3B PER - 
FAQ
What kind of company is VRDN?
VRDN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRDN?
The market cap of VRDN is approximately $2.9B, ranking 1,784 within its sector.
What is the 52-week high and low for VRDN?
VRDN has recorded a 52-week high of $34.29 and a low of $13.18.
